skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Lurtotecan Liposome (Code C1876)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lurtotecan Liposome

Definition: A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.

Label: Lurtotecan Liposome

NCI Thesaurus Code: C1876 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0935959  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
liposomal lurtotecan
liposome, lurtotecan
Lurtotecan Liposome

External Source Codes: 
PDQ Closed Trial Search ID 43473
PDQ Open Trial Search ID 43473 (check for NCI PDQ open clinical trial info)
UMLS CUI C0935959

Other Properties:
     Name Value (qualifiers indented underneath)
code C1876
Legacy_Concept_Name Lurtotecan_Liposome
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom